1. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis
   Dan Zhang et al, 2022, World Journal of Surgical Oncology CrossRef
2. Killer instincts: natural killer cells as multifactorial cancer immunotherapy
   Sarah Nersesian et al, 2023, Frontiers in Immunology CrossRef
3. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
   Robby Barnestein et al, 2022, OncoImmunology CrossRef
4. The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
   Jolanta Smok-Kalwat et al, 2023, International Journal of Molecular Sciences CrossRef
5. Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients
   Georgia Anguera et al, 2024, Biomedicines CrossRef
6. CD155 Expression in Early-Stage Lung Adenocarcinoma
   Kyoto Matsudo et al, 2024, The Annals of Thoracic Surgery CrossRef
7. Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression
   Natsumasa Nishizawa et al, 2023, Scientific Reports CrossRef
8. Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy
   Masataka Mori et al, 2023, Scientific Reports CrossRef